Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110023/S061

EverFlex self-expanding Peripheral Stent System (EverFlex)

Medtronic Vascular, Inc. · Decision date Nov 7, 2025

FDA DECISIONP110023/S061

What did the FDA approve?

FDA records P110023/S061 as a supplement to PMA P110023, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 7, 2025.

FDA approval order statement

Approval for an alternate modified stopcock from the supplier for the EverFlex self-expanding Peripheral Stent System and Protégé GPS Self-Expanding Peripheral Stent System.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Nov 7, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P110023/S061
Regulatory pathway
PMA supplement
Product code
NIP
Decision code
APPR
Decision date
Nov 7, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Product code
NIP
FDA device class
3

For the original device and its historical approval scope, see PMA P110023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110023 · Original PMA

    EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)

  2. P110023/S060 · Related supplement

    EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  3. P110023/S056 · Related supplement

    EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)

  4. P110023/S061 received

    Application receipt date recorded by FDA.

  5. P110023/S062 · Related supplement

    EverFlex Self-expanding Peripheral Stent System

  6. P110023/S061 · FDA decision

    Real-Time Process

  7. P110023/S063 · Related supplement

    EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  8. P110023/S065 · Related supplement

    EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  9. P110023/S064 · Related supplement

    EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  10. P110023/S066 · Related supplement

    EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  11. P110023/S067 · Related supplement

    Everflex Self-Expanding Peripheral Stent System, EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  12. P110023/S068 · Related supplement

    EverFlex Self-expanding Peripheral Stent System

  13. P110023/S069 · Related supplement

    EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste

  14. P110023/S070 · Related supplement

    EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)

Timeline entries are records held by MedtechLedger for P110023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110023

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA approvalMar 7, 2012FDA
Medtronic Vascular, Inc.PMA supplementJul 25, 2025FDA
Medtronic Vascular, Inc.PMA supplementAug 5, 2025FDA
Medtronic Vascular, Inc.PMA supplementOct 2, 2025FDA
Medtronic Vascular, Inc.PMA supplementFeb 9, 2026FDA
Medtronic Vascular, Inc.PMA supplementFeb 11, 2026FDA
Medtronic Vascular, Inc.PMA supplementFeb 20, 2026FDA
Medtronic Vascular, Inc.PMA supplementMar 23, 2026FDA
Medtronic Vascular, Inc.PMA supplementApr 23, 2026FDA
Medtronic Vascular, Inc.PMA supplementJul 10, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 16, 2026FDA
Medtronic Vascular, Inc.PMA supplementNov 5, 2026FDA

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3033 Campus Dr., Plymouth, MN, 55441

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records